IP Library › Granted Patent US 12673044
Granted Patent B2
US 12673044 · App. 17/439,575 · Granted Jul 7, 2026

Methods of treating borderline personality disorder

Inventors: Carlos Manuel Buesa Arjol (Castelldefels, ES); Roger Alan Bullock (Portimao, PT); José Antonio Ramos Quiroga (Barcelona, ES)
Assignee: ORYZON GENOMICS, S.A.
A61K31/4245A61P25/18
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12673044
App. No.
17/439,575
Granted
Jul 7, 2026
Kind
B2
Abstract

Provided herein are methods for treating borderline personality disorder using KDMIA inhibitors, particularly vafidemstat.

Claims (11)

1 . A method for treating one or more non-aggressive symptoms of borderline personality disorder in a patient having borderline personality disorder, comprising administering to the patient a therapeutically effective amount of a KDM1A inhibitor.

2 . The method according to claim 1 , wherein the patient to be treated is a human.

3 . The method according to claim 1 , wherein the KDM1A inhibitor is 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine, or a pharmaceutically acceptable salt or solvate thereof.

4 . The method according to claim 1 , wherein the KDM1A inhibitor is 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine.

5 . The method according to claim 1 , wherein the method comprises orally administering the KDM1A inhibitor.

6 . The method according to claim 2 , wherein the KDM1A inhibitor is 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine, or a pharmaceutically acceptable salt or solvate thereof.

7 . The method according to claim 6 , wherein the method comprises orally administering the KDM1A inhibitor.

8 . The method according to claim 2 , wherein the KDM1A inhibitor is 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine.

9 . The method according to claim 8 , wherein the method comprises orally administering the KDM1A inhibitor.

10 . A method for treating one or more non-aggressive symptoms of borderline personality disorder in a human patient having borderline personality disorder, comprising administering to the patient a therapeutically effective amount of 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine or a pharmaceutically acceptable salt or solvate thereof.

11 . A method for treating one or more non-aggressive symptoms of borderline personality disorder in a human patient having borderline personality disorder, comprising orally administering to the patient a therapeutically effective amount of 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine.